Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by Eoganacht


V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Study

Hopefully old school urologists and big pharma will listen to the experts...

October 16, 2023

V.TLT

RE:RE:RE:RE:RE:New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical Study

enriquesuave wrote: "This looks like a potential CR of 45-55% at 450...

October 16, 2023

V.TLT

RE:RE:Gasser Group in France Tests New Ruthenium and Osmium PDCs

I don't know Longholder99. Maybe someone else on this board does. What is...

October 15, 2023

V.TLT

Outstanding Encouraging Results...

Evaluation of the Antiproliferative Properties of CpRu Complexes Containing N...

October 13, 2023

V.TLT

Gasser Group in France Tests New Ruthenium and Osmium PDCs

The Gasser Group, France's equivalent of the McFarland Group, is taking a...

October 13, 2023

V.TLT

RE:RE:RE:RE:New Press Release - Theralase(R) Files US Patent for Enhanced Immunotherapy

It would be nice to see a trial with 2 cohorts - one with Rutherrin as a...

October 5, 2023

V.TLT

Interesting Interview with UBC's Peter Black

Dr. Peter Black, TLT's principal investigator for the UBC study site made...

October 3, 2023

V.TLT

RE:New research developments ready for trials

It seems to work well with mice. It uses immunotherapy, so it will be...

September 30, 2023

V.TLT

Theralase chooses most deadly over most common cancer ...

...for it's next trial There are around 300,000 GBM cases globally every...

September 27, 2023

V.TLT

RE:Clean cysto today

Congratulations! Many happy returns. Gooseybear wrote: I want to set aside...

September 26, 2023

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:Bored. Waiting. Here is some playing with data to look at.

Thanks for the great educational post Dawg. So that's how they do a urine...

September 25, 2023

V.TLT

RE:RE:RE:RE:RE:RE:Bored. Waiting. Here is some playing with data to look at.

I like the way they put it on WebMD - there is no cure for cancer but there...

September 25, 2023

V.TLT

RE:RE:RE:RE:Bored. Waiting. Here is some playing with data to look at.

Very interesting Dawg .That puts Ruvidar in an even stronger position than...

September 24, 2023

V.TLT

RE:RE:Bored. Waiting. Here is some playing with data to look at.

In a recent interview Dr. Neil Shore is enthusiastic about the significance...

September 24, 2023

V.TLT

RE:RE:RE:Bored. Waiting. Here is some playing with data to look at.

Some years ago a Theralase researcher said that the reason TLD1433 was used...

September 20, 2023

V.TLT

RE:Bored. Waiting. Here is some playing with data to look at.

It seems clear that if a patient does not have a CR at 90 days the treatment...

September 19, 2023

V.TLT

RE:Bored. Waiting. Here is some playing with data to look at.

Nice. Thanks. The statement "100% of CR at 360 stay that way at 450...

September 19, 2023

V.TLT

RE:RE:RE:Adstiladrin has BlockBuster Potential...

Theralase also brings its IP to the table. It's unproven, as they have...

September 17, 2023

V.TLT

Keytruda story

It's not just Theralase that has gone through a long and winding road...

September 15, 2023

V.TLT

RE:RE:RE:RE:RE:RE:Here's a thought

Thanks for that helpful information, wildbird1. wildbird1 wrote: Eoganacht...

September 14, 2023

Featured Company